NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Ascending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50419-0393-03 | 50419-0393 | LAROTRECTINIB | VITRAKVI | 20.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | OROPHARYNGEAL | Dec. 6, 2022 | In Use | |
65219-0550-01 | 65219-0550 | Pralatrexate | Pralatrexate | 20.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Nov. 15, 2022 | In Use | |
00574-0870-05 | 00574-0870 | Estradiol Valerate | Estradiol Valerate | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | March 31, 2010 | In Use | ||
48818-0001-01 | 48818-0001 | Pralatrexate | Folotyn | 20.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 24, 2009 | June 30, 2023 | In Use |
48818-0001-02 | 48818-0001 | Pralatrexate | Folotyn | 20.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sept. 24, 2009 | Feb. 29, 2024 | In Use |
70700-0274-22 | 70700-0274 | ESTRADIOL VALERATE | Estradiol valerate | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | May 1, 2023 | In Use | ||
00078-0669-13 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb. 1, 2016 | In Use | |
00078-0669-61 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb. 1, 2016 | In Use | |
00078-0669-84 | 00078-0669 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb. 1, 2016 | Feb. 1, 2016 | In Use |
45963-0614-51 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | March 12, 2015 | In Use | |
45963-0614-55 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | March 12, 2015 | In Use | |
45963-0614-56 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug. 11, 2018 | In Use | |
45963-0614-81 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jan. 17, 2019 | Jan. 1, 2023 | In Use |
45963-0614-85 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug. 10, 2018 | June 30, 2023 | In Use |
45963-0734-52 | 45963-0734 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 1, 2014 | June 30, 2017 | In Use |
45963-0734-54 | 45963-0734 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 1, 2014 | In Use | |
45963-0734-74 | 45963-0734 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 1, 2014 | July 31, 2017 | In Use |
00703-5656-01 | 00703-5656 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug. 1, 1996 | Jan. 31, 2024 | In Use |
00703-5656-91 | 00703-5656 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 16, 2013 | June 30, 2017 | In Use |
25021-0229-05 | 25021-0229 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | June 1, 2023 | In Use | |
60505-6272-01 | 60505-6272 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | July 1, 2023 | In Use | |
00703-5653-01 | 00703-5653 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug. 1, 1996 | In Use | |
00703-5657-01 | 00703-5657 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 1, 1997 | Aug. 31, 2022 | In Use |
00703-5657-91 | 00703-5657 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 22, 2013 | Nov. 30, 2017 | In Use |
00009-1111-01 | 00009-1111 | Irinotecan Hydrochloride | Camptosar | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 14, 1996 | Oct. 31, 2017 | In Use |
Found 10,000 results in 11 milliseconds — Export these results